Adverse outcome pathway development from protein alkylation to liver fibrosis

Archives of Toxicology

Volumn 91, Issue 4, 2017, Pages 1523-1543

  Horvat, Tomislav ^a   Landesmann, Brigitte ^a   Lostia, Alfonso ^a   Vinken, Mathieu ^b   Munn, Sharon ^a   Whelan, Maurice ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Adverse outcome pathway (AOP); Alternatives to animal testing; Liver fibrosis; Risk assessment; Systems toxicology

Indexed keywords

ADIPOCYTOKINE; COLLAGEN; LEPTIN; TRANSFORMING GROWTH FACTOR BETA1; PROTEIN;

ADVERSE OUTCOME PATHWAY; ALKYLATION; CELL DEATH; CHRONIC INFLAMMATION; CONCEPTUAL FRAMEWORK; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELL; HUMAN; KUPFFER CELL; LIVER CELL DAMAGE; LIVER FIBROSIS; MACROPHAGE ACTIVATION; NEUROENDOCRINE SYSTEM; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; ADVERSE DRUG REACTION; ANIMAL; ANIMAL TESTING ALTERNATIVE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; TOXICITY TESTING; TOXICOLOGY;

ALKYLATION; ANIMAL TESTING ALTERNATIVES; ANIMALS; CHEMICAL AND DRUG INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LIVER CIRRHOSIS; PROTEINS; RISK ASSESSMENT; TOXICITY TESTS; TOXICOLOGY;

EID: 84982267414     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-016-1814-8     Document Type: Review

References (170)

1. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ (2006) Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 43:335–344. doi:10.1002/hep.21036
2. Andres D, Sanchez-Reus I, Bautista M, Cascales M (2003) Depletion of Kupffer cell function by gadolinium chloride attenuates thioacetamide-induced hepatotoxicity. Expression of metallothionein and HSP70. Biochem Pharmacol 66:917–926
3. Ankley GT, Bennett RS, Erickson RJ et al (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29:730–741. doi:10.1002/etc.34
4. Baeck C, Wehr A, Karlmark KR et al (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416–426. doi:10.1136/gutjnl-2011-300304
5. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209–218. doi:10.1172/jci24282
6. Bauman JN, Kelly JM, Tripathy S et al (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332–340. doi:10.1021/tx800407w
7. Benyon RC, Arthur MJ (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 21:373–384. doi:10.1055/s-2001-17552
8. Berg N, De Wever B, Fuchs HW, Gaca M, Krul C, Roggen EL (2011) Toxicology in the 21st century—working our way towards a visionary reality. Toxicol In Vitro 25:874–881. doi:10.1016/j.tiv.2011.02.008
9. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58:593–608. doi:10.1016/j.jhep.2012.12.005
10. Bonecchi R, Facchetti F, Dusi S et al (2000) Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 164:3862–3869
11. Bouwens L, Baekeland M, De Zanger R, Wisse E (1986) Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 6:718–722
12. Brancatelli G, Baron RL, Federle MP, Sparacia G, Pealer K (2009) Focal confluent fibrosis in cirrhotic liver: natural history studied with serial CT. Am J Roentgenol 192:1341–1347. doi:10.2214/ajr.07.2782
13. Brenner DA (2009) Molecular pathogenesis of liver fibrosis. Trans Am Clin Climatol Assoc 120:361–368
14. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ (2002) Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123:1323–1330
15. Canbay A, Feldstein AE, Higuchi H et al (2003a) Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38:1188–1198. doi:10.1053/jhep.2003.50472
16. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ (2003b) Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83:655–663
17. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ (2004a) The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 308:1191–1196. doi:10.1124/jpet.103.060129
18. Canbay A, Friedman S, Gores GJ (2004b) Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39:273–278. doi:10.1002/hep.20051
19. Carey E, Carey WD (2010) Noninvasive tests for liver disease, fibrosis, and cirrhosis: is liver biopsy obsolete? Clevel Clin J Med 77:519–527. doi:10.3949/ccjm.77a.09138
20. Chen CZ, Raghunath M (2009) Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art. Fibrogenesis Tissue Repair 2:7. doi:10.1186/1755-1536-2-7
21. Cheng K, Yang N, Mahato RI (2009) TGF-beta1 gene silencing for treating liver fibrosis. Mol Pharm 6:772–779. doi:10.1021/mp9000469
22. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA (1999) An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 104:777–785. doi:10.1172/jci7325
23. Chu PS, Nakamoto N, Ebinuma H et al (2013) C–C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice. Hepatology 58:337–350. doi:10.1002/hep.26351
24. Codreanu SG, Ullery JC, Zhu J et al (2014) Alkylation damage by lipid electrophiles targets functional protein systems. Mol Cell Proteomics 13:849–859. doi:10.1074/mcp.M113.032953
25. Cong M, Iwaisako K, Jiang C, Kisseleva T (2012) Cell signals influencing hepatic fibrosis. Int J Hepatol 2012:158547. doi:10.1155/2012/158547
26. Connolly MK, Bedrosian AS, Mallen-St Clair J et al (2009) In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 119:3213–3225. doi:10.1172/jci37581
27. Connolly MK, Bedrosian AS, Malhotra A et al (2010) In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity. J Immunol 185:2200–2208. doi:10.4049/jimmunol.1000332
28. Constandinou C, Henderson N, Iredale JP (2005) Modeling liver fibrosis in rodents. Methods Mol Med 117:237–250. doi:10.1385/1-59259-940-0:237
29. Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B (2012) Hepatocyte–stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 72:2533–2542
30. Czaja AJ (2014) Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 20:2515–2532. doi:10.3748/wjg.v20.i10.2515
31. Czaja MJ, Weiner FR, Flanders KC et al (1989) In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol 108:2477–2482
32. De Minicis S, Seki E, Uchinami H et al (2007) Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132:1937–1946. doi:10.1053/j.gastro.2007.02.033
33. DeLeve LD (2013) Liver sinusoidal endothelial cells and liver regeneration. J Clin Invest 123:1861–1866. doi:10.1172/jci66025
34. Ding BS, Cao Z, Lis R et al (2014) Divergent angiocrine signals from vascular niche balance liver regeneration and fibrosis. Nature 505:97–102. doi:10.1038/nature12681
35. Dong L, Zhou S, Yang X, Chen Q, He Y, Huang W (2013) Magnolol protects against oxidative stress-mediated neural cell damage by modulating mitochondrial dysfunction and PI3K/Akt signaling. J Mol Neurosci 50:469–481. doi:10.1007/s12031-013-9964-0
36. El Rigal NS, Hamed MA, Rizk MZ (2013) Oxidative stress in liver diseases. IJPCR 5:155–164
37. Franceschini B, Russo C, Dioguardi N, Grizzi F (2007) Increased liver mast cell recruitment in patients with chronic C virus-related hepatitis and histologically documented steatosis. J Viral Hepat 14:549–555. doi:10.1111/j.1365-2893.2007.00859.x
38. Friedman SL (2002) Hepatic fibrosis-role of hepatic stellate cell activation. http://www.medscape.com/viewarticle/436461. Accessed 24 Aug 2015
39. Friedman SL (2003) Liver fibrosis—from bench to bedside. J Hepatol 38(Suppl 1):S38–S53
40. Friedman SL (2004) Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1:98–105. doi:10.1038/ncpgasthep0055
41. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655–1669. doi:10.1053/j.gastro.2008.03.003
42. Friedman SL (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7:425–436. doi:10.1038/nrgastro.2010.97
43. Fujiwara N, Kobayashi K (2005) Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 4:281–286
44. Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530. doi:10.1007/s00204-013-1078-5
45. Gressner AM, Weiskirchen R (2006) Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 10:76–99
46. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7:793–807
47. Gressner AM, Gao CF, Gressner OA (2009) Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 15:2433–2440
48. Guo J, Friedman SL (2007) Hepatic fibrogenesis. Semin Liver Dis 27:413–426. doi:10.1055/s-2007-991517
49. Guo J, Friedman SL (2010) Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 3:21. doi:10.1186/1755-1536-3-21
50. Hammerich L, Bangen JM, Govaere O et al (2014) Chemokine receptor CCR6-dependent accumulation of gammadelta T cells in injured liver restricts hepatic inflammation and fibrosis. Hepatology 59:630–642. doi:10.1002/hep.26697
51. Harty MW, Muratore CS, Papa EF et al (2010) Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol 176:1271–1281. doi:10.2353/ajpath.2010.090527
52. Henderson NC, Iredale JP (2007) Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond) 112:265–280. doi:10.1042/cs20060242
53. Hillebrandt S, Wasmuth HE, Weiskirchen R et al (2005) Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37:835–843. doi:10.1038/ng1599
54. Hristova M, Spiess PC, Kasahara DI, Randall MJ, Deng B, van der Vliet A (2012) The tobacco smoke component, acrolein, suppresses innate macrophage responses by direct alkylation of c-Jun N-terminal kinase. Am J Respir Cell Mol Biol 46:23–33. doi:10.1165/rcmb.2011-0134OC
55. Ide M, Kuwamura M, Kotani T, Sawamoto O, Yamate J (2005) Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J Comp Pathol 133:92–102. doi:10.1016/j.jcpa.2005.01.011
56. Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539–548. doi:10.1172/jci30542
57. Iwaisako K, Brenner DA, Kisseleva T (2012) What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 27(Suppl 2):65–68. doi:10.1111/j.1440-1746.2011.07002.x
58. Jaeschke H (2011) Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J Gastroenterol Hepatol 26(Suppl 1):173–179. doi:10.1111/j.1440-1746.2010.06592.x
59. Jennings P, Schwarz M, Landesmann B et al (2014) SEURAT-1 liver gold reference compounds: a mechanism-based review. Arch Toxicol 88:2099–2133. doi:10.1007/s00204-014-1410-8
60. Johnson A, DiPietro LA (2013) Apoptosis and angiogenesis: an evolving mechanism for fibrosis. FASEB J 27:3893–3901. doi:10.1096/fj.12-214189
61. Kaimori A, Potter J, Kaimori JY, Wang C, Mezey E, Koteish A (2007) Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 282:22089–22101. doi:10.1074/jbc.M700998200
62. Kamimura S, Tsukamoto H (1995) Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology 22:1304–1309
63. Kaplowitz N (2002) Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 22:137–144. doi:10.1055/s-2002-30100
64. Katz SC, Ryan K, Ahmed N et al (2011) Obstructive jaundice expands intrahepatic regulatory T cells, which impair liver T lymphocyte function but modulate liver cholestasis and fibrosis. J Immunol 187:1150–1156. doi:10.4049/jimmunol.1004077
65. Kavlock RJ, Austin CP, Tice RR (2009) Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal 29:485–487; discussion 492–497. doi:10.1111/j.1539-6924.2008.01168.x
66. Kehrer JP, Biswal SS (2000) The molecular effects of acrolein. Toxicol Sci 57:6–15
67. Kern JC, Kehrer JP (2002) Acrolein-induced cell death: a caspase-influenced decision between apoptosis and oncosis/necrosis. Chem Biol Interact 139:79–95
68. Kershenobich Stalnikowitz D, Weissbrod AB (2003) Liver fibrosis and inflammation. A review. Ann Hepatol 2:159–163
69. Kirkham P (2007) Oxidative stress and macrophage function: a failure to resolve the inflammatory response. Biochem Soc Trans 35:284–287. doi:10.1042/bst0350284
70. Kisseleva T, Brenner DA (2007) Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 22(Suppl 1):S73–S78. doi:10.1111/j.1440-1746.2006.04658.x
71. Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 233:109–122. doi:10.3181/0707-mr-190
72. Kisseleva T, Brenner DA (2011) Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol 25:305–317. doi:10.1016/j.bpg.2011.02.011
73. Kolios G, Valatas V, Kouroumalis E (2006) Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 12:7413–7420
74. Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485–517. doi:10.1146/annurev.immunol.021908.132710
75. Krewski D, Acosta D Jr, Andersen M et al (2010) Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 13:51–138. doi:10.1080/10937404.2010.483176
76. Landesmann B, Goumenou M, Munn S, Whelan M (2012) Description of prototype modes-of-action related to repeated dose toxicity. JRC Scientific and Policy Report 75689. http://publications.jrc.ec.europa.eu/repository/bitstream/JRC75689/lb-na-25631-en-n.pdf. Accessed 24 Aug 2015
77. Langhans B, Kramer B, Louis M et al (2013) Intrahepatic IL-8 producing Foxp3(+)CD4(+) regulatory T cells and fibrogenesis in chronic hepatitis C. J Hepatol 59:229–235. doi:10.1016/j.jhep.2013.04.011
78. Leask A, Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816–827. doi:10.1096/fj.03-1273rev
79. LeCluyse EL, Witek RP, Andersen ME, Powers MJ (2012) Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42:501–548. doi:10.3109/10408444.2012.682115
80. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485. doi:10.1056/NEJMra021844
81. Lee UE, Friedman SL (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195–206. doi:10.1016/j.bpg.2011.02.005
82. Li JT, Liao ZX, Ping J, Xu D, Wang H (2008) Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol 43:419–428. doi:10.1007/s00535-008-2180-y
83. Liang Y, Jie Z, Hou L et al (2013) IL-33 induces nuocytes and modulates liver injury in viral hepatitis. J Immunol 190:5666–5675. doi:10.4049/jimmunol.1300117
84. Liebler DC (2008) Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol 21:117–128. doi:10.1021/tx700235t
85. Liedtke C, Luedde T, Sauerbruch T et al (2013) Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 6:19. doi:10.1186/1755-1536-6-19
86. Lim YS, Kim WR (2008) The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 12:733–746, vii. doi:10.1016/j.cld.2008.07.007
87. Liu Y (2011) Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7:684–696. doi:10.1038/nrneph.2011.149
88. Liu X, Hu H, Yin JQ (2006) Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 26:8–22. doi:10.1111/j.1478-3231.2005.01192.x
89. Liu C, Tao Q, Sun M et al (2010) Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 90:1805–1816. doi:10.1038/labinvest.2010.123
90. Lopez-Novoa JM, Nieto MA (2009) Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1:303–314. doi:10.1002/emmm.200900043
91. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A (2005) Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45:605–628. doi:10.1146/annurev.pharmtox.45.120403.095906
92. Luckey SW, Petersen DR (2001) Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fibrosis in rats. Exp Mol Pathol 71:226–240. doi:10.1006/exmp.2001.2399
93. Malhi H, Guicciardi ME, Gores GJ (2010) Hepatocyte death: a clear and present danger. Physiol Rev 90:1165–1194. doi:10.1152/physrev.00061.2009
94. Manibusan MK, Odin M, Eastmond DA (2007) Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 25:185–209. doi:10.1080/10590500701569398
95. Marra F (2002) Chemokines in liver inflammation and fibrosis. Front Biosci 7:1899–1914
96. Mastellos D, Papadimitriou JC, Franchini S, Tsonis PA, Lambris JD (2001) A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J Immunol 166:2479–2486
97. Matsuoka M, Tsukamoto H (1990) Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 11:599–605
98. Meek ME, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R (2014) Mode of action human relevance (species concordance) framework: evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol 34:595–606. doi:10.1002/jat.2984
99. Mehta N, Ozick LA, Gbadehan E (2014) Drug-induced hepatotoxicity. http://emedicine.medscape.com/article/169814. Accessed 24 Aug 2015
100. Milani S, Herbst H, Schuppan D et al (1994) Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 144:528–537
101. Moghe A, Ghare S, Lamoreau B, Mohammad M, Barve S, McClain C, Joshi-Barve S (2015) Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci 143:242–255. doi:10.1093/toxsci/kfu233
102. Mohammad MK, Avila D, Zhang J, Barve S, Arteel G, McClain C, Joshi-Barve S (2012) Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress. Toxicol Appl Pharmacol 265:73–82. doi:10.1016/j.taap.2012.09.021 Epub 2012 Sept 28
103. Muhanna N, Doron S, Wald O et al (2008) Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology 48:963–977. doi:10.1002/hep.22413
104. Nakamura I, Zakharia K, Banini BA et al (2014) Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling. PLoS ONE 9:e92273. doi:10.1371/journal.pone.0092273
105. Natarajan SK, Thomas S, Ramamoorthy P et al (2006) Oxidative stress in the development of liver cirrhosis: a comparison of two different experimental models. J Gastroenterol Hepatol 21:947–957. doi:10.1111/j.1440-1746.2006.04231.x
106. Novobrantseva TI, Majeau GR, Amatucci A et al (2005) Attenuated liver fibrosis in the absence of B cells. J Clin Invest 115:3072–3082. doi:10.1172/jci24798
107. O’Brien PJ, Irwin W, Diaz D et al (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580–604. doi:10.1007/s00204-006-0091-3
108. OECD (2013) Guidance document on developing and assessing adverse outcome pathways, series on testing and assessment No. 184. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono%282013%296&doclanguage=en. Accessed 24 Aug 2015
109. OECD (2014) Users’ handbook supplement to the guidance document for developing and assessing AOPs. https://aopkb.org/common/AOP_Handbook.pdf. Accessed 24 Aug 2015
110. Orrenius S, Nicotera P, Zhivotovsky B (2011) Cell death mechanisms and their implications in toxicology. Toxicol Sci 119:3–19. doi:10.1093/toxsci/kfq268
111. Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA (2014) Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 20:2854–2872. doi:10.1089/ars.2013.5619
112. Parola M, Robino G (2001) Oxidative stress-related molecules and liver fibrosis. J Hepatol 35:297–306
113. Parsons CJ, Takashima M, Rippe RA (2007) Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 22(Suppl 1):S79–S84. doi:10.1111/j.1440-1746.2006.04659.x
114. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181–194. doi:10.1038/nri3623
115. Poli G (2000) Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 21(3):49–98
116. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825–832
117. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H (1999) Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 96:2345–2349
118. Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62:481–492. doi:10.1136/jcp.2008.058248
119. Ramaiah SK, Jaeschke H (2007) Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol 35:757–766. doi:10.1080/01926230701584163
120. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB (2010) Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603–1616. doi:10.1016/j.freeradbiomed.2010.09.006
121. Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE (2007) Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol Sci 96:2–15. doi:10.1093/toxsci/kfl173
122. Rockey DC, Friedman SL (2006) Hepatic fibrosis and cirrhosis. In: Boyer TD, Manns MP, Sanyal AJ, Zakim D (eds) Zakim and Boyer’s hepatology, 5th edn. Elsevier, Philadelphia, pp 87–109
123. Rockey DC, Boyles JK, Gabbiani G, Friedman SL (1992) Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24:193–203
124. Roth S, Michel K, Gressner AM (1998) (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 27:1003–1012. doi:10.1002/hep.510270416
125. Roy J, Pallepati P, Bettaieb A, Tanel A, Averill-Bates DA (2009) Acrolein induces a cellular stress response and triggers mitochondrial apoptosis in A549 cells. Chem Biol Interact 181:154–167. doi:10.1016/j.cbi.2009.07.001
126. Russmann S, Kullak-Ublick GA, Grattagliano I (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16:3041–3053
127. Safadi R, Friedman SL (2002) Hepatic fibrosis—role of hepatic stellate cell activation. MedGenMed 4:27
128. Safadi R, Ohta M, Alvarez CE et al (2004) Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 127:870–882
129. Saito JM, Bostick MK, Campe CB, Xu J, Maher JJ (2003) Infiltrating neutrophils in bile duct-ligated livers do not promote hepatic fibrosis. Hepatol Res 25:180–191
130. Sanchez-Valle V, Chavez-Tapia NC, Uribe M, Mendez-Sanchez N (2012) Role of oxidative stress and molecular changes in liver fibrosis: a review. Curr Med Chem 19:4850–4860
131. Scholten D, Weiskirchen R (2011) Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury. Hepatology 53:1048–1051. doi:10.1002/hep.24191
132. Schumann J, Wolf D, Pahl A et al (2000) Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol 157:1671–1683. doi:10.1016/s0002-9440(10)64804-3
133. Schuppan D, Kim YO (2013) Evolving therapies for liver fibrosis. J Clin Invest 123:1887–1901. doi:10.1172/jci66028
134. Seok J, Warren HS, Cuenca AG et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110:3507–3512. doi:10.1073/pnas.1222878110
135. Shi Z, Wakil AE, Rockey DC (1997) Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 94:10663–10668
136. Singh R, Czaja MJ (2007) Regulation of hepatocyte apoptosis by oxidative stress. J Gastroenterol Hepatol 22(Suppl 1):S45–S48. doi:10.1111/j.1440-1746.2006.04646.x
137. Sivakumar P, Das AM (2008) Fibrosis, chronic inflammation and new pathways for drug discovery. Inflamm Res 57:410–418. doi:10.1007/s00011-008-7166-y
138. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I (2013) models for liver toxicity testing. Toxicol Res (Camb) 2:23–39. doi:10.1039/c2tx20051a
139. Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA (2009) Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology 50:1512–1523. doi:10.1002/hep.23186
140. Sugihara A, Tsujimura T, Fujita Y, Nakata Y, Terada N (1999) Evaluation of role of mast cells in the development of liver fibrosis using mast cell-deficient rats and mice. J Hepatol 30:859–867
141. Tacke F, Zimmermann HW (2014) Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 60:1090–1096. doi:10.1016/j.jhep.2013.12.025
142. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ (2003) Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 37:87–95. doi:10.1053/jhep.2003.50002
143. Takehara T, Tatsumi T, Suzuki T et al (2004) Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127:1189–1197
144. Tan AB, Kress S, Castro L, Sheppard A, Raghunath M (2013) Cellular re- and de-programming by microenvironmental memory: why short TGF-beta1 pulses can have long effects. Fibrogenesis Tissue Repair 6:12. doi:10.1186/1755-1536-6-12
145. Tanel A, Averill-Bates DA (2007) Activation of the death receptor pathway of apoptosis by the aldehyde acrolein. Free Radic Biol Med 42:798–810. doi:10.1016/j.freeradbiomed.2006.12.009
146. Tang LX, He RH, Yang G et al (2012) Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLoS ONE 7:e31350. doi:10.1371/journal.pone.0031350
147. Thompson CA, Burcham PC (2008) Protein alkylation, transcriptional responses and cytochrome c release during acrolein toxicity in A549 cells: influence of nucleophilic culture media constituents. Toxicol In Vitro 22:844–853. doi:10.1016/j.tiv.2007.12.018
148. Thompson KJ, McKillop IH, Schrum LW (2011) Targeting collagen expression in alcoholic liver disease. World J Gastroenterol 17:2473–2481. doi:10.3748/wjg.v17.i20.2473
149. Tukov FF, Maddox JF, Amacher DE, Bobrowski WF, Roth RA, Ganey PE (2006) Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro 20:1488–1499. doi:10.1016/j.tiv.2006.04.005
150. van Agthoven M, Metselaar HJ, Tilanus HW, de Man RA, IJzermans JN, Martin van Ineveld BM (2001) A comparison of the costs and effects of liver transplantation for acute and for chronic liver failure. Transpl Int 14:87–94
151. Van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P (2007) Liver fibrosis in vitro: cell culture models and precision-cut liver slices. Toxicol In Vitro 21:545–557. doi:10.1016/j.tiv.2006.12.009
152. Villeneuve DL, Crump D, Garcia-Reyero N et al (2014) Adverse outcome pathway (AOP) development I: strategies and principles. Toxicol Sci 142:312–320. doi:10.1093/toxsci/kfu199
153. Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312:158–165. doi:10.1016/j.tox.2013.08.011
154. Vinken M (2015) Adverse outcome pathways and drug-induced liver injury testing. Chem Res Toxicol 28:1391–1397. doi:10.1021/acs.chemrestox.5b00208
155. Vinken M, Landesmann B, Goumenou M et al (2013) Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Toxicol Sci 136:97–106. doi:10.1093/toxsci/kft177
156. Wang K, Lin B, Brems JJ, Gamelli RL (2013) Hepatic apoptosis can modulate liver fibrosis through TIMP1 pathway. Apoptosis 18:566–577. doi:10.1007/s10495-013-0827-5
157. Wells RG (2010) The epithelial-to-mesenchymal transition in liver fibrosis: here today, gone tomorrow? Hepatology 51:737–740. doi:10.1002/hep.23529
158. Westra IM, Oosterhuis D, Groothuis GM, Olinga P (2014) The effect of antifibrotic drugs in rat precision-cut fibrotic liver slices. PLoS ONE 9:e95462. doi:10.1371/journal.pone.0095462
159. Williams EJ, Gaca MD, Brigstock DR, Arthur MJ, Benyon RC (2000) Increased expression of connective tissue growth factor in fibrotic human liver and in activated hepatic stellate cells. J Hepatol 32:754–761
160. Winwood PJ, Arthur MJ (1993) Kupffer cells: their activation and role in animal models of liver injury and human liver disease. Semin Liver Dis 13:50–59. doi:10.1055/s-2007-1007337
161. Wynn TA (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4:583–594. doi:10.1038/nri1412
162. Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117:524–529. doi:10.1172/jci31487
163. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210. doi:10.1002/path.2277
164. Xie G, Wang X, Wang L et al (2012) Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 142(918–927):e6. doi:10.1053/j.gastro.2011.12.017
165. Xie G, Choi SS, Syn WK et al (2013) Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut 62:299–309. doi:10.1136/gutjnl-2011-301494
166. Xu J, Lee G, Wang H, Vierling JM, Maher JJ (2004) Limited role for CXC chemokines in the pathogenesis of alpha-naphthylisothiocyanate-induced liver injury. Am J Physiol Gastrointest Liver Physiol 287:G734–G741. doi:10.1152/ajpgi.00300.2003
167. Xu R, Zhang Z, Wang FS (2012) Liver fibrosis: mechanisms of immune-mediated liver injury. Cell Mol Immunol 9:296–301. doi:10.1038/cmi.2011.53
168. Yin C, Evason KJ, Asahina K, Stainier DY (2013) Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 123:1902–1910. doi:10.1172/jci66369
169. Zeisberg M, Yang C, Martino M et al (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282:23337–23347. doi:10.1074/jbc.M700194200
170. Zhan SS, Jiang JX, Wu J et al (2006) Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 43:435–443. doi:10.1002/hep.21093